We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+18.21%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.8B
AUM Growth
+$1.86B
Cap. Flow
-$1.4B
Cap. Flow %
-14.24%
Top 10 Hldgs %
73.27%
Holding
123
New
14
Increased
15
Reduced
12
Closed
2

Top Buys

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$247M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$188M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$112M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$91.9M
5
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$75.9M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$67.4M
2
XOMA
Xoma
XOMA
+$26.3M
3
AMBI
Ambit Biosciences Corp
AMBI
+$16.8M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$14.3M
5
RPRX
Repros Therapeutics Inc.
RPRX
+$6.64M

Sector Composition

Rank Sector Weight
1 Healthcare 42.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCYC
1
DELISTED
PHARMACYCLICS INC
PCYC
$1.12B 11.39%
9,129,231
-527,368
-5% -$67.4M
INCY icon
2
Incyte
INCY
$25.5B
$1.09B 11.08%
14,845,559
– –
GEVA
3
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$989M 10.1%
10,660,432
– –
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
$895M 9.14%
27,861,720
+5,385,991
+24% +$188M
AVNR
5
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$653M 6.66%
38,513,713
+17,539,036
+84% +$247M
ACAD icon
6
Acadia Pharmaceuticals
ACAD
$4.43B
$650M 6.64%
20,481,442
– –
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$437M 4.46%
13,656,318
+700
+0% +$22.8K
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$12B
$336M 3.43%
3,713,950
+1,343,486
+57% +$112M
ANAC
9
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$136M 1.38%
4,204,702
– –
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.43B
$130M 1.33%
10,713,686
– –
BLCM
11
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$98.7M 1.01%
+428,373
New +$91.9M
DYAX
12
DELISTED
DYAX CORPORATION
DYAX
$86.6M 0.88%
6,157,789
– –
CERS icon
13
Cerus
CERS
$575M
$73M 0.75%
11,702,727
-237,451
-2% -$1.08M
SLXP
14
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$73M 0.75%
635,321
+626,700
+7,269% +$75.9M
VNDA icon
15
Vanda Pharmaceuticals
VNDA
$302M
$64M 0.65%
4,472,153
+100,000
+2% +$1.18M
XOMA
16
DELISTED
Xoma
XOMA
$60.8M 0.62%
846,201
-307,373
-27% -$26.3M
XNPT
17
DELISTED
XENOPORT, INC.
XNPT
$60.5M 0.62%
6,903,628
+87,851
+1% +$645K
ARAV
18
DELISTED
Aravive, Inc. Common Stock
ARAV
$51.2M 0.52%
380,291
+172,609
+83% +$20.2M
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$44.1M 0.45%
2,380,074
– –
DBVT
20
DBV Technologies
DBVT
$800M
$41.2M 0.42%
+151,923
New +$39.1M
PGNX
21
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$33.6M 0.34%
4,449,797
– –
DSCI
22
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$32.9M 0.34%
3,537,137
– –
TGTX icon
23
TG Therapeutics
TGTX
$8.28B
$32.5M 0.33%
2,050,313
– –
ACOR
24
DELISTED
Acorda Therapeutics
ACOR
$30.9M 0.32%
6,296
+18
+0.3% +$77.2K
HALO icon
25
Halozyme
HALO
$9.88B
$26.8M 0.27%
2,776,143
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2014 Portfolio in Review

As of Q4 2014, Baker Bros. Advisors held 123 positions worth $9.8B, up 23% from $7.94B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Baker Bros. Advisors withdrew a net $1.4B in Q4 2014, closing 2 positions and reducing 12 holdings. Its most notable exit was Ambit Biosciences Corp, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 39% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Bellicum Pharmaceuticals, Inc. worth $98.7M.

  • Baker Bros. Advisors's largest Q4 2014 buy was Bellicum Pharmaceuticals, Inc.: 428,373 shares worth $98.7M.
  • Baker Bros. Advisors added most to AVANIR PHARMACEUTICALS, INC CL A in Q4 2014, an estimated $247M increase.
  • Baker Bros. Advisors's biggest Q4 2014 reduction was PHARMACYCLICS INC, cutting an estimated $67.4M.
  • Baker Bros. Advisors fully exited Ambit Biosciences Corp in Q4 2014, selling an estimated $16.8M.
  • Baker Bros. Advisors's ten largest holdings make up 73% of its $9.8B portfolio in Q4 2014.
  • Baker Bros. Advisors opened 14 new positions and closed 2 in Q4 2014.
  • Baker Bros. Advisors's portfolio value rose 23% quarter-over-quarter to $9.8B.

Based on Baker Bros. Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.